4 292

Cited 43 times in

Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

Authors
 Kim H.S.  ;  Hong M.H.  ;  Kim K.b  ;  Shin S.-J.  ;  Ahn J.-B.  ;  Jeung H.C.  ;  Chung H.C.  ;  Koh Y.  ;  Lee S.-H.  ;  Bang Y.-J.  ;  Rha S.Y. 
Citation
 ONCOLOGY, Vol.80(5-6) : 395-405, 2011 
Journal Title
 ONCOLOGY 
ISSN
 0030-2414 
Issue Date
2011
MeSH
Adult ; Aged ; Anemia/chemically induced ; Antineoplastic Agents/administration & dosage* ; Antineoplastic Agents/adverse effects* ; Asian Continental Ancestry Group* ; Carcinoma, Renal Cell/drug therapy* ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Indoles/administration & dosage* ; Indoles/adverse effects* ; Kidney Neoplasms/drug therapy* ; Male ; Middle Aged ; Neutropenia/chemically induced ; Nomograms ; Predictive Value of Tests ; Pyrroles/administration & dosage* ; Pyrroles/adverse effects* ; Republic of Korea ; Risk Factors ; Thrombocytopenia/chemically induced ; Treatment Outcome
Keywords
Renal cell cancer ; Sunitinib ; Toxicity
Abstract
OBJECTIVE: We aimed to describe the efficacy and safety of sunitinib in unselected Korean advanced renal cell carcinoma (RCC) patients. PATIENTS AND METHODS: From November 2005 to August 2008, 132 histologically confirmed advanced RCC patients (100 in the global expanded access program) were enrolled. Response and toxicity were assessed regularly according to the protocol. RESULTS: Within this population, 82.6% had clear cell RCC, and 28.8% were treatment naïve. Patients received a median of 5 cycles of sunitinib (range 1-30), and the mean relative dose intensity was 82.0 ± 14.20 (SD). The progression-free survival (PFS) and overall survival rates were 8.2 and 23.1 months, respectively. For the 130 evaluable patients, the objective response rate was 34.1% (n = 45); 44.7% (n = 59) exhibited stable disease. Reasons for discontinuation were disease progression (75.0%) and toxicity (7.6%). The most frequent adverse events were thrombocytopenia (75.0%), neutropenia (70.5%), and anemia (69.7%). Low body surface area (OR = 4.2, 95% CI 1.2-13.8, p = 0.02) and previously treated status (OR = 3.1, 95% CI 1.3-7.4, p = 0.01) were highly predictive of grade 3-4 toxicities. Based on these findings, a nomogram predicting the probability of 12-month PFS was constructed, giving a concordance index of 0.675. CONCLUSIONS: Despite the different toxicity profiles, maintaining adequate dose modifications and a careful follow-up enables comparable treatment outcomes for unselected Korean advanced RCC patients
Full Text
http://www.karger.com/Article/FullText/330361
DOI
10.1159/000330361
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Oral Cancer Research Institute (구강종양연구소) > 1. Journal Papers
Yonsei Authors
Kim, Ki Yeol(김기열) ORCID logo https://orcid.org/0000-0001-5357-1067
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
Hong, Min Hee(홍민희) ORCID logo https://orcid.org/0000-0003-3490-2195
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93652
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse